Literature DB >> 18348306

Significance of HER2 and C-MYC oncogene amplifications in breast cancer in atomic bomb survivors: associations with radiation exposure and histologic grade.

Shiro Miura1, Masahiro Nakashima, Masahiro Ito, Hisayoshi Kondo, Serik Meirmanov, Tomayoshi Hayashi, Midori Soda, Takeshi Matsuo, Ichiro Sekine.   

Abstract

BACKGROUND: It has been postulated that radiation induces breast cancers in atomic bomb (A-bomb) survivors. Oncogene amplification is an important mechanism during breast carcinogenesis and also serves as an indicator of genomic instability (GIN). The objective of this study was to clarify the association of oncogene amplification in breast cancer in A-bomb survivors with radiation exposure.
METHODS: In total, 593 breast cancers were identified in A-bomb survivors from 1968 to 1999, and the association between breast cancer incidence and A-bomb radiation exposure was evaluated. Invasive ductal cancers from 67 survivors and 30 nonsurvivors were analyzed for amplification of the HER2 and C-MYC genes by fluorescence in situ hybridization, and expression levels of hormone receptors were analyzed by immunostaining.
RESULTS: The incidence rate increased significantly as exposure distance decreased from the hypocenter (hazard ratio per 1-km decrement, 1.47; 95% confidence interval [95% CI], 1.30-1.66). The incidence of HER2 and C-MYC amplification was increased significantly in the order of the control group, the distal group (P = .0238), and the proximal group (P = .0128). Multivariate analyses revealed that distance was a risk factor for the coamplification of C-MYC and HER2 in breast cancer in survivors (odds ratio per 1-km increment, 0.17; 95% CI, 0.01-0.63). The histologic grade of breast cancers became significantly higher in the order of the control group, the distal group, and the proximal group and was associated with oncogene amplifications.
CONCLUSIONS: The current results suggested that A-bomb radiation may affect the development of oncogene amplification by inducing GIN and may be associated with a higher histologic grade in breast cancer among A-bomb survivors. (c) 2008 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18348306     DOI: 10.1002/cncr.23414

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Nuclear EGFR suppresses ribonuclease activity of polynucleotide phosphorylase through DNAPK-mediated phosphorylation at serine 776.

Authors:  Yung-Luen Yu; Ruey-Hwang Chou; Chia-Han Wu; Ying-Nai Wang; Wei-Jung Chang; Yen-Ju Tseng; Wei-Chao Chang; Chien-Chen Lai; Hong-Jen Lee; Longfei Huo; Chung-Hsuan Chen; Mien-Chie Hung
Journal:  J Biol Chem       Date:  2012-07-19       Impact factor: 5.157

2.  Significance of genomic instability in breast cancer in atomic bomb survivors: analysis of microarray-comparative genomic hybridization.

Authors:  Masahiro Oikawa; Koh-ichiro Yoshiura; Hisayoshi Kondo; Shiro Miura; Takeshi Nagayasu; Masahiro Nakashima
Journal:  Radiat Oncol       Date:  2011-12-07       Impact factor: 3.481

3.  c-MYC is a radiosensitive locus in human breast cells.

Authors:  M A Wade; N J Sunter; S E Fordham; A Long; D Masic; L J Russell; C J Harrison; V Rand; C Elstob; N Bown; D Rowe; C Lowe; G Cuthbert; S Bennett; S Crosier; C M Bacon; K Onel; K Scott; D Scott; L B Travis; F E B May; J M Allan
Journal:  Oncogene       Date:  2014-12-22       Impact factor: 9.867

4.  Interstitial chromosomal deletion of the tuberous sclerosis complex 2 locus is a signature for radiation-associated renal tumors in Eker rats.

Authors:  Tatsuya Inoue; Toshiaki Kokubo; Kazuhiro Daino; Hiromi Yanagihara; Fumiko Watanabe; Chizuru Tsuruoka; Yoshiko Amasaki; Takamitsu Morioka; Shino Homma-Takeda; Toshiyuki Kobayashi; Okio Hino; Yoshiya Shimada; Shizuko Kakinuma
Journal:  Cancer Sci       Date:  2020-02-03       Impact factor: 6.716

5.  Characterization of genomic alterations in radiation-associated breast cancer among childhood cancer survivors, using comparative genomic hybridization (CGH) arrays.

Authors:  Xiaohong R Yang; J Keith Killian; Sue Hammond; Laura S Burke; Hunter Bennett; Yonghong Wang; Sean R Davis; Louise C Strong; Joseph Neglia; Marilyn Stovall; Rita E Weathers; Leslie L Robison; Smita Bhatia; Kiyohiko Mabuchi; Peter D Inskip; Paul Meltzer
Journal:  PLoS One       Date:  2015-03-12       Impact factor: 3.240

Review 6.  Role of DUSP1/MKP1 in tumorigenesis, tumor progression and therapy.

Authors:  Jiliang Shen; Yaping Zhang; Hong Yu; Bo Shen; Yuelong Liang; Renan Jin; Xiaolong Liu; Liang Shi; Xiujun Cai
Journal:  Cancer Med       Date:  2016-05-26       Impact factor: 4.452

7.  MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.

Authors:  Andrew R Green; Mohammed A Aleskandarany; Devika Agarwal; Somaia Elsheikh; Christopher C Nolan; Maria Diez-Rodriguez; R Douglas Macmillan; Graham R Ball; Carlos Caldas; Srinivasan Madhusudan; Ian O Ellis; Emad A Rakha
Journal:  Br J Cancer       Date:  2016-03-08       Impact factor: 7.640

Review 8.  Adverse outcome pathways for ionizing radiation and breast cancer involve direct and indirect DNA damage, oxidative stress, inflammation, genomic instability, and interaction with hormonal regulation of the breast.

Authors:  Jessica S Helm; Ruthann A Rudel
Journal:  Arch Toxicol       Date:  2020-05-13       Impact factor: 5.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.